Opthea Completes Recruitment in Phase 2a Clinical Trial of OPT-302 for Diabetic Macular Edema

NEXT STORY
Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook
PREV STORY
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates

author_avatar
NASDAQ Market News

Teleflex Reports Second Quarter 2020 Results

author_avatar
NASDAQ Market News

Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

author_avatar
NASDAQ Market News